92 related articles for article (PubMed ID: 21925097)
1. Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children.
Schlegel P; Teltschik HM; Pfeiffer M; Handgretinger R; Schumm M; Koscielniak E; Feuchtinger T; Klingebiel T; Bader P; Schlegel PG; Greil J; Lang P
Best Pract Res Clin Haematol; 2011 Sep; 24(3):443-52. PubMed ID: 21925097
[TBL] [Abstract][Full Text] [Related]
2. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
3. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
[TBL] [Abstract][Full Text] [Related]
4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
5. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors.
Lang P; Pfeiffer M; Teltschik HM; Schlegel P; Feuchtinger T; Ebinger M; Klingebiel T; Bader P; Schlegel PG; Beck J; Greil J; Handgretinger R
Best Pract Res Clin Haematol; 2011 Sep; 24(3):403-11. PubMed ID: 21925093
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation.
Liu KY; Chen YH; Liu DH; Xu LP; Huang XJ
Bone Marrow Transplant; 2008 Oct; 42(8):535-9. PubMed ID: 18641681
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell transplantation in children with hematological malignancies across HLA barriers--reasonable alternative?
Sedlácek P; Starý J; Vodváková S; Poloucková A; Gasová Z; Marinov I; Formánková R
Neoplasma; 2001; 48(4):302-6. PubMed ID: 11712683
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF
J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458
[TBL] [Abstract][Full Text] [Related]
12. Mismatched T cell-depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia.
Aversa F; Terenzi A; Felicini R; Tabilio A; Falzetti F; Carotti A; Falcinelli F; Sodani P; Amici A; Zucchetti P; Mazzarino I; Martelli MF
Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S29-32. PubMed ID: 9989886
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome after haploidentical stem cell transplantation in children.
Lang P; Greil J; Bader P; Handgretinger R; Klingebiel T; Schumm M; Schlegel PG; Feuchtinger T; Pfeiffer M; Scheel-Walter H; Führer M; Martin D; Niethammer D
Blood Cells Mol Dis; 2004; 33(3):281-7. PubMed ID: 15528145
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects.
Lang P; Pfeiffer M; Müller I; Schumm M; Ebinger M; Koscielniak E; Feuchtinger T; Föll J; Martin D; Handgretinger R
Klin Padiatr; 2006; 218(6):321-6. PubMed ID: 17080334
[TBL] [Abstract][Full Text] [Related]
16. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
18. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
[TBL] [Abstract][Full Text] [Related]
19. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]